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ABSTRACT 
Objective: The aim of this work was to enhance the bioavailability of poorly soluble, anti-emetic drug; domperidone (DMP) having a poor oral 
bioavailability (13-17%) due to extensive first pass metabolism. The goal of this study was achieved through solubilization of DMP using solid 
dispersion technology followed by incorporation of solid dispersions into sublingual tablets to bypass pre-systemic metabolism. 
Methods: Solid dispersions of DMP with Pluronic F-68 were prepared in different weight ratios by fusion method and they were evaluated for their 
in vitro dissolution rate to select the best ratio for final formulation. Then, solid dispersions were formulated into sublingual tablets in combination 
with various soluble excipients. Sublingual tablets were prepared by direct compression technique and evaluated for their physical properties, in 
vitro dissolution rate and kinetics of drug release. The best formulae were selected for in vivo studies in rabbits in comparison with marketed oral 
tablets; Motinorm®. 
Results: Solid dispersions of DMP with Pluronic F-68 in a weight ratio of 1:7 (w/w) showed the highest dissolution rate and were selected for 
sublingual tablets formulation. Sublingual tablets formulae S16 (containing Fructose and 10% w/w Ac-Di-Sol) and S20 (containing Fructose and 
10% w/w Explotab) showed the best results and were selected for in vivo studies in rabbits. The selected formulae showed marked enhancement of 
DMP bioavailability compared with the commercial oral tablets; Motinorm®, with relative bioavailability values of 432.49±10.13% and 
409.32±11.59 % for S16 and S20, respectively. 
Conclusion: The results confirmed that sublingual tablets were an effective tool for DMP delivery with marked enhancement of bioavailability. 
Keywords: Domperidone, Solubility, Solid dispersions, Sublingual tablets, First-pass metabolism, Bioavailability 
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INTRODUCTION 
The first-pass metabolism is a critical challenge that faces effective 
oral delivery of many drugs. It means extensive metabolism of the 
drug in the gut wall and liver before reaching systemic circulation 
resulting in poor bioavailability and low efficacy of drug [1]. 
Researchers have developed several approaches to overcome the 
first-pass metabolism including rectal [2], buccal [3] and 
transdermal drug delivery systems [4]. Sublingual tablets have 
become one of the top promising approaches for this purpose due to 
their ease of administration, rapid disintegration in the mouth and 
instant drug delivery which is very useful for emergency 
management of many health disorders [1]. Poor water solubility of 
many drugs limits the ability for their delivery via sublingual route 
[1]. Solid dispersion technology has provided the solution for 
solubility problems of an enormous number of drugs [5]. Domperidone 
(DMP) is 5-chloro-1-[1-[3-(2, 3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
propyl] 4-piperidinyl]-1, 3-dihydro-2H-benz-imidazol-2-one. It is a 
dopamine (D2) receptor antagonist. DMP is used for the treatment and 
prevention of acute nausea and vomiting of any cause; especially 
cytotoxic therapy and radiotherapy [6]. According to Biopharmaceutical 
Classification System (BCS), DMP is classified under class-II drugs which 
are poorly soluble and highly permeable [6].  
It is practically insoluble in water (1 part in 50 000 part of water) [7] 
with poor oral bioavailability (13-17%) due to extensive first-pass 
metabolism in the gut wall and liver [8]. The aim of this study was to 
improve DMP bioavailability via formulation of sublingual tablets. 
DMP was solubilized through the formulation of solid dispersions with 
Pluronic F-68 in different weight ratios by fusion method and the 
prepared systems were evaluated for their in vitro dissolution rate to 
select the best ratio for final formulation. Then, solid dispersions were 
incorporated into sublingual tablets in combination with various 
soluble excipients including Sorbitol, Mannitol, Anhydrous lactose and 
Fructose. Sublingual tablets were prepared by direct compression 
technique and evaluated for their weight uniformity, drug content, 
friability, hardness, thickness, diameter, disintegration time and in 
vitro dissolution rate. The best formulae were selected for in vivo 
studies in rabbits in comparison with marketed oral tablets; 
Motinorm®. 
MATERIALS AND METHODS 
Materials 
-Domperidone was supplied as a gift sample by "Pharco, for 
pharmaceutical and chemical industry", Egypt. 
-Pluronic F-68 and Polyethylene glycol 6000 (PEG 6000) were 
purchased from "Sigma-Aldrich Co.", USA. 
-Sorbitol, Mannitol, Fructose, and Ac-Di-Sol were purchased from 
"Cooperation Pharmaceutique Francaise", France. 
-Anhydrous lactose was purchased from "Prolabo", France. 
-Explotab was purchased from "BDH Co.", UK. 
-Motinorm® tablets were supplied by "Glaxo Smith Kline", Egypt.  
-Adult male Newzeland rabbits (average body weight = 2 kg) were 
obtained from the animal house, Faculty of Medicine, Assiut 
University, Assiut, Egypt. 
-Thiopental sodium was supplied by "Pharco, for pharmaceutical 
and chemical industry", Egypt.  
-All other used chemicals and reagents were of analytical grade and 
were used as received. 
Methods 
Fourier-transform infrared (FT-IR) studies 
A qualitative FT-IR analysis was performed for drug, excipients and 
their physical mixtures (1:1 w/w) to check the drug-excipient 
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compatibility using FT-IR spectrometer (Shimadzu IR-470, Japan). 
Samples of 1-2 mg were mixed with potassium bromide (IR grade) 
and compressed into discs in a compressor unit under vacuum and 
then scanned from 4000 to 400 cm-1 with an empty pellet holder as a 
reference. 
Differential scanning calorimetry (DSC) studies  
DSC studies were performed for drug, excipients and their physical 
mixtures (1:1 w/w) to check the drug-excipient compatibility. DSC 
thermo grams were obtained by using a shimadzu DSC-50 (Japan) 
equipped with a computer software program. Samples of about 5 mg 
were placed in an aluminum pan of 50 µl capacity and 0.1 mm 
thickness, press-sealed with an aluminum cover of 0.1 mm 
thickness. An empty pan sealed in the same way was used as a 
reference. Samples were heated from 30 °C to 300 °C at a rate of 10 
°C min-1 and a nitrogen flow of 25 ml/min. Indium was used as a 
standard for calibrating temperature. Thermograms obtained were 
analyzed using TA-50 program to determine temperature and heat 
of fusion (ΔH) for each peak. 
Preparation of DMP solid dispersions 
Solid dispersions of DMP with Pluronic F-68 were prepared in 
weight ratios of 1:1, 1:3, 1:5 and 1:7 w/w by fusion method. The 
calculated amount of Pluronic F-68 was placed in a porcelain dish 
and heated till melting over a steam bath. The accurately weighed 
amount of DMP was dispersed into molten Pluronic F-68 gradually 
using a glass rod. After complete dispersion of drug within carrier, 
the dish was removed from the steam bath and left aside to cool at 
room temperature till solidification of its contents. Then, the solid 
dispersion formed was pulverized, sieved to obtain a particle size 
range of 125-250 µm and stored in a dessicator over calcium 
chloride till used [9]. 
In vitro dissolution rate study of DMP from the prepared solid 
dispersions 
USP dissolution apparatus II (Erweka, Germany) was used at a 
rotation speed of 50 r. p. m. Powdered samples of solid dispersions 
equivalent to 10 mg of domperidone were added to the dissolution 
medium (250 ml phosphate buffer solution with pH 6.8, kept at 
37±0.5 °C). The pure drug was sieved to obtain a size range of 125-
250 µm and treated similarly. At time intervals of 5, 15, 30, 45, 60, 
90 and 120 min, samples (5 ml) of the solution were withdrawn with 
a volumetric pipette using the cotton plug as a filter and replaced 
with an equal volume of fresh dissolution medium equilibrated at 
37±0.5 °C. The samples were analyzed for the released amount of 
DMP spectrophotometrically at λmax of 284 nm. Each experiment was 
performed in triplicate and the mean recordings were used for 
calculations. The solid dispersions of DMP with Pluronic F-68 in a 
weight ratio of 1:7 (w/w) showed the highest dissolution rate and 
thus; this ratio was selected for being used in the formulation of 
sublingual tablets. 
Formulation of DMP sublingual tablets 
Sublingual tablets of DMP were prepared by the direct compression 
technique using the formulae shown in tables (1-3). A fixed amount 
(80 mg) of DMP-Pluronic F-68 solid dispersion in a weight ratio of 
1:7 (w/w) was used in the formulations which was equivalent to 10 
mg of DMP. Different water-soluble diluents were used including 
Sorbitol, Anhydrous lactose, Mannitol and Fructose, which also 
imparted a sweet taste to tablets which would be useful in 
enhancing patient acceptability. Ac-Di-Sol and Explotab were used as 
super disintegrants to promote fast disintegration of tablets and 
they were incorporated in different concentrations of the final tablet 
weight (200 mg). Polyethylene glycol 6000 (PEG 6000) was used as 
a water-soluble lubricant in a concentration of 4% (w/w). All 
powders were mixed by trituration in a glass mortar with a pestle to 
obtain a uniform mixture. The blended powders were compressed 
into tablets weighing 200 mg using a single punch tablet machine 
(Erweka, Germany) having a die set of 8 mm diameter. 
Physical evaluation of the prepared sublingual tablets 
Uniformity of tablets weight 
According to European Pharmacopoeia 2014 [7], twenty randomly 
selected tablets from each formula were individually weighed. The 
average weight was determined and the standard deviation was 
calculated. For tablets weighing 80-250 mg, tablet weight should not 
deviate from claimed value by more than 7.5%. 
Uniformity of drug content 
The European Pharmacopoeia 2014 method was adopted [7]. Ten 
tablets were randomly selected from each formula and assayed 
individually. A pre-weighed tablet was powdered, transferred into a 
100 ml volumetric flask and the volume was completed to 100 ml 
with methanol. The contents of the flask were stirred continuously 
and filtered. After suitable dilution with phosphate buffer solution 
(pH 6.8), the solution was assayed spectrophotometrically at 284 
nm. Drug content was expressed as a percentage of label claim and 
should be 100±15%. 
 
Table 1: Composition of formulated sublingual tablets of DMP containing different water-soluble diluents 
Formula composition (mg)a Ingredients 
S4 S3 S2 S1 
80 80 80 80 Solid dispersion 
- - - 112 Sorbitol 
- - 112 - Anhydrous lactose 
- 112 - - Mannitol 
112 - - - Fructose 
8 8 8 8 PEG 6000 
- - - - Ac-Di-Sol 
- - - - Explotab 
a Total tablet weight= 200 mg. 
 
Table 2: Composition of formulated sublingual tablets of DMP containing different water-soluble diluents and 5% (w/w) super-disintegrants 
     Formula composition (mg) a Ingredients 
S12 S11 S10 S9 S8 S7 S6 S5 
80 80 80 80 80 80 80 80 Solid dispersion 
- - - 102 - - - 102 Sorbitol 
- - 102 - - - 102 - Anhydrous lactose 
- 102 - - - 102 - - Mannitol 
102 - - - 102 - - - Fructose 
8 8 8 8 8 8 8 8 PEG 6000 
- - - - 10 10 10 10 Ac-Di-Solb 
10 10 10 10 - - - - Explotabb 
aTotal tablet weight= 200 mg., bThe used amounts of Ac-Di-Sol or Explotab represent 5% (w/w) of the total tablet weight. 
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Table 3: Composition of formulated sublingual tablets of DMP containing different water-soluble diluents and 10% (w/w) super-disintegrants 
     Formula composition (mg) a Ingredients 
S20 S19 S18 S17 S16 S15 S14 S13 
80 80 80 80 80 80 80 80 Solid dispersion 
- - - 92 - - - 92 Sorbitol 
- - 92 - - - 92 - Anhydrous lactose 
- 92 - - - 92 - - Mannitol 
92 - - - 92 - - - Fructose 
8 8 8 8 8 8 8 8 PEG 6000 
- - - - 20 20 20 20 Ac-Di-Sol b 
20 20 20 20 - - - - Explotab b 
aTotal tablet weight= 200 mg., bThe used amounts of Ac-Di-Sol or Explotab represent 10% (w/w) of the total tablet weight. 
 
Tablet friability 
According to European Pharmacopoeia 2014 [7], the friability of the 
prepared tablets was evaluated by calculating the percentage loss in 
the weight of 20 tablets from each formula after the revolution in a 
friabilator (Erweka, Germany) at 25 r. p. m. for 4 min. The tablets 
were brushed gently to remove the adhered powder. The percentage 
of weight loss was calculated using the following equation:  
Weight loss (%) = ((weight of tablets before testing–weight of 
tablets after testing)/weight of tablets before testing) X 100. The 
percentage of weight loss should not exceed 1%. 
Tablet hardness 
The hardness of the prepared tablets was determined by means of 
the Erweka hardness tester (Erweka, Germany). For each batch, the 
hardness of 10 randomly-selected tablets was determined and the 
average was considered [10]. 
Thickness and diameter of the prepared tablets 
The thickness and the diameter of 20 randomly-selected tablets 
from each formula were measured by means of a micrometer 
(Mitutoyo Co., Japan). The average thickness and diameter were 
determined [11]. 
Disintegration time of the prepared tablets 
According to European Pharmacopoeia 2014 [7], the test was carried out 
on randomly selected 6 tablets using the apparatus specified in the 
pharmacopoeia (Erweka, Germany). 250 ml phosphate buffer solution 
(pH 6.8) at 37±0.5 °C was used as a disintegration medium and the time 
taken for complete disintegration of the tablet with no solid mass 
remaining in the apparatus was measured. For sublingual tablets, 
disintegration time should be less than 3 min. 
In vitro dissolution rate of DMP from the prepared sublingual 
tablets 
USP dissolution apparatus II (Erweka, Germany) was used at a 
rotation speed of 50 r. p. m. Each of the tested tablets was added to 
the dissolution medium (250 ml phosphate buffer solution with pH 
6.8, kept at 37±0.5 °C). At time intervals of 5, 10, 15, 20, 25 and 30 
min, samples (5 ml) of the solution were withdrawn with a 
volumetric pipette using the cotton plug as a filter and replaced with 
an equal volume of fresh dissolution medium equilibrated at 37±0.5 
°C. The samples were analyzed spectrophotometrically at λmax of 284 
nm. Each experiment was performed in triplicate, and the mean 
recordings were used for calculations. 
Kinetic analysis of the drug releases data 
The mechanism of drug release from each formulation was 
determined by linear regression analysis according to zero-order, 
first-order and Higuchi-diffusion models. The correlation coefficient 
(r) values were calculated for each model. The highest value of the 
calculated correlation coefficients assigned the mechanism of the 
drug release from the prepared tablets. The drug release data were 
fitted to the following equations [12]:  
Zero-order model: Mt/M∞ = K0t.  
First-order model: Mt/M∞ = e-K1t. 
Higuchi-diffusion model: Mt/M∞ = kH t½.  
Where (Mt/M∞) is the fractional release of the drug at time t, k0 = 
Zero-order rate constant, k1 = First-order rate constant, kH = Higuchi 
rate constant and t = time of release.  
Then, the release data were analyzed using the equation proposed 
by Korsemeyer and Peppas [12]: Mt/M∞ = Kt n. 
Where Mt/M∞ is the fractional release of the drug at time t, K is the 
release rate constant and n is the diffusional exponent that 
characterizes the type of release mechanism during the dissolution 
process. In the case of tablets (cylindrical sample), n= 0.45 for 
Fickian diffusion while in the case of Non-Fickian release, the value 
of n falls between 0.45 and 0.89. For zero-order release (case II 
transport), n= 0.89 and for super case II transport, n>0.89. 
In vivo studies on the selected formulae 
Treatment of animals 
On basis of the previously mentioned tests, formulae S16 (containing 
Fructose and 10% w/w Ac-Di-Sol) and S20 (containing Fructose and 
10% w/w Explotab) showed the best results and thus; they were 
selected for in vivo studies in rabbits in comparison with the 
commercial oral tablets; Motinorm®. The protocol of the study was 
approved by Medical Ethics Committee, Faculty of Medicine, Assiut 
University, Egypt (IRB no: IRB00008718). 24 healthy adult male 
Newzeland rabbits weighing 1.8-2.2 Kg (average body weight= 2 Kg) 
were used and housed at room temperature. The food was withheld 
for 24 h before the experiment, but the rabbits had free access to tap 
water. A specific equation was used to calculate the rabbit drug dose 
equivalent to human dose based on body surface area ratio between 
rabbit and man [13]. The rabbits were divided into 4 groups; each 
consisted of 6 rabbits. The first group was considered as a control 
and received no dosage forms. The 2nd group rabbits were given an 
oral dose of 0.514 mg/kg of DMP (equivalent to 10 mg per human 
tablet dose) from Motinorm® tablets using a stomach tube. The 
3rdand 4th groups were anesthetized using IP Thiopental sodium (15 
mg/kg) before administration of 0.514 mg/kg DMP sublingually 
from formulae S16 and S20, respectively to prevent the rabbits from 
swallowing the tablets. Blood samples of about 1-2 ml were 
withdrawn via an indwelling catheter in the marginal ear vein into a 
5 ml screw-capped heparinized centrifuge tubes at the following 
time points: pre-dose, 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 and 
24 h following drug administration. The samples were centrifuged at 
5000 r. p. m for 15 min. The supernatant was removed and 
transferred into a new screw-capped centrifuge tube. This separated 
plasma was stored at-20 °C until analysis.  
Assay of drug in plasma  
The HPLC method developed by Sivakumar et al. was adopted [14]. 
The mobile phase was a filtered and degassed mixture of methanol, 
acetonitrile, and triethylamine solution (10 mM, pH 7.0±0.05 
adjusted with 85% phosphoric acid) in a ratio of 20:33:47 (v/v). To 
0.1 ml of each plasma sample, 0.5 µg of Acetophenone as an internal 
standard (0.1 ml of a 5 µg/ml standard solution in the mobile phase) 
and 2 ml of acetonitrile were added. The extraction was carried out 
by vortexing the samples for 10 min followed by centrifugation at 
5000 r. p. m for another 10 min. After precipitation of plasma 
proteins, the organic layer was separated and then, transferred into 
a Pyrex conical tube. The solvent was evaporated and the solid residues 
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were reconstituted into 100 µl of the mobile phase. Then, 20 µl samples 
were injected directly into HPLC column (Venusil x BP C-18 column, 250 
x 4.60 mm, 5 µm). The mobile phase flow rate was 1 ml/min and UV 
detection was performed at 285 nm. Chromatograms were recorded, 
and the peak areas were calculated using Young Lin Autochrom-3000 
software. All analysis was performed at room temperature; the assay 
was done in triplicates and the mean was considered. 
Pharmacokinetic analysis of data 
Pharmacokinetic parameters were determined from plasma 
concentration-time curve as the following [15, 16]: 
The maximum plasma concentration (Cmax) and the time to attain the 
peak concentration (Tmax) were obtained directly from the curve. 
The absorption rate constant (Kabs) was obtained by the method of 
residuals. The elimination rate constant (Kel.) was calculated from 
the terminal linear portion of the semi-logarithmic plot of plasma 
concentration versus time curve using linear regression analysis. 
The apparent half-lives of absorption and elimination (t½) were 
obtained by dividing 0.693 by the corresponding rate constant. The 
area under plasma concentration-time curve from zero to end time 
(AUC0-t) and the area under the first moment curve from zero to end 
time (AUMC0-t) were calculated by using linear trapezoidal rule. AUC 
and AUMC from zero-time to infinity (AUC0-∞ and AUMC 0-∞) were 
calculated by the following equations : 
AUC(0-∞) = AUC(0-t)+(Ct/Kel.) 
AUMC (0-∞) = AUMC (0-t)+t. Ct/Kel.+Ct/Kel.2 
Where, Ct is the last measurable concentration at the end time point 
(t), Kel. is the elimination rate constant of the drug. The mean 
residence time of the drug in the body (MRT) was calculated using 
the following equation: MRT = AUMC (0-∞)/AUC(0-∞). Total clearance of 
the drug (ClT) was calculated as dose divided by AUC (0-∞). The 
apparent volume of distribution (Vd) was obtained by extrapolation 
method. Relative bioavailability FR (%) was obtained from the 
comparison of the AUC of each of the tested formula divided by that 











The data were presented as mean values ±SD. Student's t-test was 
performed for data derived from the pharmacokinetic parameters in 
order to investigate the statistical significance (*p<0.05) of the 
difference between each of the tested sublingual formulations and 
the commercial Motinorm® tablets using a statistical computer 
package (SPSS version 13.0) 
RESULTS AND DISCUSSION 
Fourier-transform infrared (FT-IR) studies 
Table (4) shows the FT-IR frequencies of DMP with the different 
excipients used in the formulation of sublingual tablets. Pure DMP 
showed characteristic peaks at 3390 cm-1 (N-H stretching vibration), 
3080 cm-1(aromatic =C-H stretching vibration), 2915 cm-1 (sp3–C-H 
vibration), 1697 cm-1 (C=O stretching vibration) and several bands 
at 1400-1600 cm1 (aromatic C=C stretching vibration). The same 
characteristic peaks of DMP appeared in the physical mixtures with 
excipients (1:1 w/w) without significant changes. These results 
confirmed the absence of chemical incompatibilities between drug 
and the used excipients. FT-IR spectra of DMP with Anhydrous 
lactose are shown in fig. (1) as a representative example. 
 
Table 4: FT-IR frequencies of DMP with the different excipients used in the formulation of sublingual tablets 
FT-IR frequencies (cm-1) DMP characteristic groups 
DMP-excipients physical mixtures (1:1 w/w) Pure DMP 
Explotab Ac-Di-Sol PEG 
6000 
Fructose Mannitol Sorbitol Anhydrous 
lactose 
3395 3385 3412 3395 3402 3405 3400 3390 N-H  
3090 3097 3075 3085 3090 3070 3050 3080 aromatic =C-H  
2950 2971 2962 2970 2950 2901 2890 2915 sp3–C-H  





















Fig. 1: FT-IR spectra of DMP (A), Anhydrous lactose (B) and 1:1 (w/w) physical mixture of them (C) 
Younis et al. 
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Differential scanning calorimetry (DSC) studies 
Table (5) shows the temperature and heat of fusion (ΔH) 
obtained from DSC spectra of DMP with the different excipients 
used in the formulation of sublingual tablets. Pure DMP showed 
a sharp melting endothermic peak at 252.49 °C with a fusion 
enthalpy (ΔH) of (-94.37 J/g). This indicated that the drug was 
present in a pure crystalline state. Each of individual excipients 
showed a melting endothermic peak corresponding to its melting 
point. DMP-excipients physical mixtures (1:1 w/w) showed no 
significant shift in the position of melting endothermic peak of DMP, 
but with a reduction in the intensity and fusion enthalpy due to 
dilution effect [17]. These results confirmed the absence of chemical 
incompatibilities between drug and the investigated excipients and 
indicated the suitability of their use in the formulations. DSC 
thermograms of DMP with Anhydrous lactose are shown in fig. (2) as 
a representative example. 
In vitro dissolution rate study of DMP from the prepared solid 
dispersions 
Fig. 3 shows the release profiles of DMP from its different solid 
dispersions with Pluronic F-68 in comparison with the pure drug. It 
was obvious that DMP had a very poor dissolution rate at pH 6.8 
(only 16 % of the drug released after 2 h) which could be attributed 
to its weakly-basic nature (pka=7.9) making it insoluble at relatively 
high pH values [17]. All prepared solid dispersions showed higher 
dissolution rates than the pure drug. This can be explained as when 
solid dispersions are exposed to aqueous media, the carrier 
dissolves, and the drug is released as very fine colloidal particles. 
This greatly reduces particle size and increases surface area, which 
results in marked improvement of dissolution rates [5]. Increasing 
the amount of carrier in solid dispersion system increased the 
dissolution rate (the percent of dissolution improvement was 371.88 
%, 487.46 %, 714.28 % and 937.2 % for 1:1, 1:3, 1:5 and 1:7 w/w 
solid dispersions, respectively in comparison with the pure drug). 
Solid dispersions of DMP with Pluronic F-68 in a weight ratio of 1:7 
showed the highest dissolution rate and thus; this ratio was selected 
for being used in the formulation of sublingual tablets. 
Physical evaluation of the prepared sublingual tablets 
The results revealed that all prepared tablets had uniform weight 
(195-205.5 mg), thickness (2.36-2.56 mm) and diameter (7.92-8.11 
mm) and showed acceptable results regarding their drug content 
and friability according to the previously-mentioned specifications. 
The tablet hardness values ranged from 2.4-5.5 kg/cm2which were 
suitable values for sublingual tablets. So, the tablets were accepted 
to be used for further studies.  
Formulae S1-S4 containing no super disintegrants showed 
unacceptable disintegration times longer than 3 min. The addition of 
5% (w/w) super disintegrant decreased tablet disintegration time due 
to wicking and capillary action exerted by super disintegrant which 
resulted in the faster disintegration of tablet upon contact with water 
[18]. Increasing super disintegrant concentration in tablets from 5% to 
10% (w/w) resulted in shorter disintegration time (less than 1.5 min). 
Tablets containing Ac-Di-Sol showed shorter disintegration time than 
those containing Explotab. This can be attributed to slow water uptake 
and the gelling tendency of Explotab that delay its effect [18]. 
 
Table 5: Peak temperatures and enthalpy changes (∆H) for DSC thermograms of DMP alone and its physical mixtures with the 
investigated excipients (1:1 w/w) 
Samples Peak temperature of the drug ( °C) ∆H (J/g) 
DMP alone 252.49 -94.37 
DMP: Anhydrous lactose 248.00 -23.00 
DMP: Sorbitol 248.50 -27.47 
DMP: Mannitol 245.74 -42.55 
DMP: Fructose 249.8 -39.17 
DMP: PEG 6000 248.36 -32.26 
DMP: Ac-Di-Sol 250.80 -32.51 
DMP: Explotab 249.11 -44.49 
 
 
Fig. 2: DSC thermograms of DMP (A), Anhydrous lactose (B) and 1:1 (w/w) physical mixture of them (C) 
Younis et al. 




Fig. 3: Release profiles of DMP from its different solid 
dispersions with Pluronic F-68 at pH 6.8 in comparison with the 
pure drug (Number of experiments; n=3, results are expressed 
as mean±SD) 
 
In vitro dissolution rate of DMP from the prepared sublingual 
tablets 
Fig. (4) Shows the in vitro release profiles of DMP from sublingual 
tablets containing water-soluble different diluents and 10% (w/w) 
Ac-Di-Sol. It was obvious that all tablets showed fast drug release 
with more than 80% of drug released within the first 5 min. The 
order of drug release from the different tablets was: Fructose-
containing tablets ˃ Sorbitol-containing tablets ˃ Anhydrous lactose-
containing tablets stelbat gniniatnoc-lotinnaM >. This can be 
explained on the basis of the difference in aqueous solubility of these 
sugars [10]. It was observed that the prepared tablets exhibited 
surface erosion upon contact with water. The speed of surface 
erosion depends mainly on the solubility of the matrix [10]. Fructose 
has the highest aqueous solubility among the investigated sugars 
followed by Sorbitol, Anhydrous lactose and finally, Mannitol [19]. 
 
 
Fig. 4: In vitro release profiles of DMP from sublingual tablets 
containing different water-soluble diluents and 10% (w/w) Ac-
Di-Sol (Number of experiments; n=3, results are expressed as 
mean±SD) 
 
Kinetic analysis of the drug release data from the sublingual tablets 
Kinetic analysis of DMP release data from sublingual tablets 
revealed that all prepared tablets showed simplified Higuchi-
diffusion model. Analysis of the dissolution data using the equation 
proposed by Korsemeyer and Peppas gave values of n (release 
exponent) that lied between 0.45 and 0.89 in all the investigated 
formulae exhibiting a non-fickian release behavior which was 
controlled by a combination of diffusion and chain relaxation 
mechanisms [11]. 
In vivo studies on the selected formulae of DMP sublingual tablets 
According to the previous results, it was obvious that formulae S16 
(containing Fructose and 10% w/w Ac-Di-Sol) and S20 (containing 
Fructose and 10% w/w Explotab) showed the best physical 
properties and release profiles and thus; they were selected for in 
vivo studies in rabbits in comparison with the commercial oral 
tablets; Motinorm®. The mean plasma levels profiles versus time 
obtained after administration of S16, S20 and Motinorm® are shown 
in fig. (5). Higher peak plasma concentrations (Cmax) were achieved 
after administration of S16 and S20 tablets compared with 
Motinorm® tablets (2.32±0.12, 2.14±0.08 and1.11±0.13 µg/ml, 
respectively). Also, higher AUC values were obtained with the 
sublingual tablets S16 and S20 compared with Motinorm® tablets 
(relative bioavailability values were 432.49±10.13% and 
409.32±11.59% for S16 and S20, respectively). These results 
confirmed that sublingual tablets resulted in enhancement of DMP 
bioavailability through overcoming the first-pass metabolism 
following oral administration of drug [20]. Sublingual tablets 
showed shorter Tmax values than oral tablets indicating faster 
absorption of them. The elimination half-lives of DMP were 
7.12±0.52, 7.73±0.48 and 7.69±0.35 h and the apparent volume of 
distribution values were 0.11±0.03, 0.13±0.05 and 0.12±0.06 l/kg 
for S16, S20 and Motinorm®, respectively. Pharmacokinetic 
parameters of the investigated tablets and their statistical 
significance are listed in tables (6 and 7). 
 
 
Fig. 5: Plasma concentrations of DMP after oral administration 
of Motinorm® and sublingual administration of formula S16 and 
formula S20 tablets at a dose level of 0.514 mg/kg (Number of 
experiments; n=6, results are expressed as mean±SD) 
 
Table 6: Pharmacokinetic parameters of formula S16 sublingual tablets compared with Motinorm® oral tablets and statistical significance 
of the difference between them 
Significance of the difference b Motinorm® tablets S16 tablets Pharmacokinetic parametersa 
Significant 1.11±0.13 2.32±0.12 Cmax (µg/ml) 
Significant 0.50±0.16 0.25±0.06 Tmax (h) 
Significant 3.06±1.70 5.18±1.26 Kabs (h-1) 
Significant 0.23±0.08 0.13±0.03 t½ (abs) (h) 
Significant 7.02±1.47 30.36±3.38 AUC(0-24 hr) (µg. h/ml) 
Significant 7.02±1.47 30.36±3.38 AUC(0-∞) (µg. h/ml) 
Significant 98.55±4.27 477.82±26.24 AUMC(0-24 hr) (µg. h2/ml) 
Significant 98.55±4.27 477.82±26.24 AUMC(0-∞) (µg. h2/ml) 
Significant 14.04±0.44 15.74±0.48 MRT (h) 
Significant 2.61±0.09 0.60±0.07 ClT (ml/min) 
 aNumber of experiments; n=6, results are expressed as mean±SD., bStatistically-significant when (*p<0.05), statistically non-significant when 
(*p>0.05). 
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Table 7: Pharmacokinetic parameters of formula S20 sublingual tablets compared with Motinorm® oral tablets and statistical significance 
of the difference between them 
Significance of the difference b Motinorm® tablets S20 tablets Pharmacokinetic parameters a 
Significant 1.11±0.13 2.14±0.08 Cmax (µg/ml) 
Significant 0.50±0.16 0.25±0.05 Tmax (h) 
Significant 3.06±1.70 4.88±1.37 Kabs (h-1) 
Significant 0.23±0.08 0.14±0.02 t½ (abs) (h) 
Significant 7.02±1.47 28.73±2.99 AUC(0-24 hr) (µg. h/ml) 
Significant 7.02±1.47 28.73±2.99 AUC(0-∞) (µg. h/ml) 
Significant 98.55±4.27 447.95±18.29 AUMC(0-24 hr) (µg. h2/ml) 
Significant 98.55±4.27 447.95±18.29 AUMC(0-∞) (µg. h2/ml) 
Significant 14.04±0.44 15.59±0.29 MRT (h) 
Significant 2.61±0.09 0.64±0.09 ClT (ml/min) 




The dissolution rate of DMP was markedly improved through the 
formulation of solid dispersions with Pluronic F-68. The incorporation 
of these solid dispersions with various excipients into sublingual 
tablets resulted in physically-acceptable tablets. Tablet disintegration 
study revealed that incorporation of super disintegrants into tablets 
resulted in faster tablet disintegration and indicated the superiority of 
Ac-Di-Sol over Explotab. Increasing the super disintegrant 
concentration in tablets decreased the disintegration time. All the 
prepared sublingual tablets showed improved patterns of drug release 
and Fructose-containing tablets were the best among them. Formulae 
S16 (containing Fructose and 10% w/w Ac-Di-Sol) and S20 (containing 
Fructose and 10% w/w Explotab) showed the best physical properties 
and release profiles and were selected for in vivo studies in rabbits which 
revealed a marked enhancement of DMP bioavailability in comparison 
with the marketed Motinorm® oral tablets. 
ACKNOWLEDGEMENT 
The authors are grateful to Faculty of Pharmacy, Assiut University, 
Egypt for supporting and facilitating the work. Also, the authors are 
grateful to Pharco, for pharmaceutical and chemical industry, Egypt 
for gifting domperidone. 
CONFLICT OF INTERESTS 
The authors report no conflict of interests in this work 
REFERENCES 
1. Bind AK, Gnanarajan G, Kothiyal P. A review: sublingual route 
for systemic drug delivery. Int J Drug Res Technol 2013;3:31-6. 
2. Ibrahim EH, El-Faham TH, Mohammed FA, El-Eraky NS. 
Formulation, in vitro release and bioavailability study of 
domperidone rectal suppositories. Int J Innovations Pharm Sci 
2012;1:8-14. 
3. Dixit YD, Suruse PB, Shivhare UD. Formulation and evaluation 
of mucoadhesive buccal tablet of domperidone maleate. 
Indones J Pharm 2013;24:47–55. 
4. Akhter S, Jain GK, Ahmad FJ, Khar RK, Jain N, Khan ZI, et al. 
Investigation of nanoemulsion system for transdermal delivery 
of domperidone: ex-vivo and in vivo studies. Curr Nanosci 
2008;4:381-90. 
5. Dalvi PB, Gerange AB, Ingale PR. Solid dispersion: a strategy to 
enhance solubility. J Drug Delivery Ther 2015;5:20-8. 
6. Reena T, Vandana D. Enhancement of solubility and dissolution 
rate of domperidone using cogrinding and kneading technique. 
J Drug Delivery Ther 2012;2:152-8. 
7. Council of Europe, editor. European Pharmacopoeia. 8th ed. 
Strasbourg: European Directorate for the Quality of Medicines 
and Health Care; 2014.  
8. Bardal SK, Waechter JE, Martin DS. Applied pharmacology. 
Missouri: Elsevier Saunders; 2011. 
9. Zaki RM, Ali AA, El Menshawi SF, Abdel Bary A. Effect of binary 
and ternary solid dispersions prepared by fusion method on 
the dissolution of poorly water soluble diacerein. Int J Drug 
Delivery 2013;5:99-109. 
10. Hassan MA, Ibrahim AS, Abd El-Mohsen MG, El-Shanawany SM. 
Formulation and evaluation of famotidine sublingual tablets. 
Bull Pharm Sci Assiut Univ 2005;28:149-57. 
11. Aboutaleb AE, Abdel-Rahman AA, Samy EM, El-Naggar MG. 
Formulation and evaluation of verapamil hydrochloride 
buccoadhesive tablets. Unique J Pharm Biol Sci 2013;1:48-57. 
12. Fouad EA, Ibrahim MA, El-Badry M. Embedment of 
chlorpheniramine maleate in directly compressed matrix 
tablets of compritol and kollidone SR. Trop J Pharm Res 
2015;14:371-7. 
13. Rajasekaran UB, Nayak US. How to choose drug dosage for 
human experiments based on drug dose used on animal 
experiments: a review. IJSS Case Reports Rev 2014;1:31-2. 
14. Sivakumar T, Manavalan R, Valliappan K. Development and 
validation of a reversed-phase HPLC method for simultaneous 
determination of domperidone and pantoprazole in 
pharmaceutical dosage forms. Acta Chromatographica 2007; 
18:130-42. 
15. Muhammad IN, Shoaib MH, Yousuf RI. Pharmacokinetics and 
bioequivalence studies of oral cefuroxime axetil 250 mg tablets 
in healthy human subjects. J Bioequivalence Bioavailability 
2014;6:149-52.  
16. Shanthakumar GS, Narayanacharyulu R, Divakar G. 
Pharmacokinetic evaluation of bilayered buccoadhesive 
compacts containing enalapril maleate using rabbits. Int J 
Pharm Pharm Res 2015;2:66-75. 
17. Aboutaleb AE, Abdel-Rahman SI, Ahmed MO, Younis MA. 
Enhancement of domperidone dissolution rate via formulation of 
adsorbates and co-adsorbates. Int J Pharm Sci Res 2016;7:951-60. 
18. Sudheer K, Naidu SS, kantipotu CS, Senthilkumar M, 
Sreenivasulu V, Naveenkumar K. Formulation and in vitro 
characterization of orodispersible salbutamol sulphate tablets. 
Int J Adv Pharm Res 2012;3:1106-15. 
19. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical 
excipients. 6th ed. London: Pharmaceutical Press; 2009. 
20. Verma H, Verma S, Prasad SB, Singh H. Sublingual delivery of 
frovatriptan: an indication of the potential alternative route. 
Int Scholarly Res Not 2014:1-9. Doi.org/10.1155/2014/ 675868.  
[Article in press]. 
 
